Nicorette Strongmint lozenge 4 mg + Niquitin MiniMint lozenge 4 mg
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tobacco Dependence
Conditions
Tobacco Dependence
Trial Timeline
Mar 20, 2017 → Jun 29, 2017
NCT ID
NCT03130179About Nicorette Strongmint lozenge 4 mg + Niquitin MiniMint lozenge 4 mg
Nicorette Strongmint lozenge 4 mg + Niquitin MiniMint lozenge 4 mg is a phase 1 stage product being developed by Johnson & Johnson for Tobacco Dependence. The current trial status is completed. This product is registered under clinical trial identifier NCT03130179. Target conditions include Tobacco Dependence.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03130179 | Phase 1 | Completed |
Competing Products
20 competing products in Tobacco Dependence